Cargando…

Circulating miR-146a predicts glucocorticoid response in thyroid eye disease

OBJECTIVE: Thyroid eye disease (TED) is an immune-mediated disorder of the eye. Intravenous glucocorticoid (GC) is the first-line treatment for patients with active moderate-to-severe TED. However, the response rate is between 50% and 80%. There are still no simple and reliable markers of responsive...

Descripción completa

Detalles Bibliográficos
Autores principales: Manso, Jacopo, Censi, Simona, Clausi, Cristina, Piva, Ilaria, Zhu, Yi Hang, Mondin, Alberto, Pedron, Maria Chiara, Barollo, Susi, Bertazza, Loris, Midena, Giulia, Parrozzani, Raffaele, Mian, Caterina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563606/
https://www.ncbi.nlm.nih.gov/pubmed/37606076
http://dx.doi.org/10.1530/ETJ-23-0083
_version_ 1785118368578142208
author Manso, Jacopo
Censi, Simona
Clausi, Cristina
Piva, Ilaria
Zhu, Yi Hang
Mondin, Alberto
Pedron, Maria Chiara
Barollo, Susi
Bertazza, Loris
Midena, Giulia
Parrozzani, Raffaele
Mian, Caterina
author_facet Manso, Jacopo
Censi, Simona
Clausi, Cristina
Piva, Ilaria
Zhu, Yi Hang
Mondin, Alberto
Pedron, Maria Chiara
Barollo, Susi
Bertazza, Loris
Midena, Giulia
Parrozzani, Raffaele
Mian, Caterina
author_sort Manso, Jacopo
collection PubMed
description OBJECTIVE: Thyroid eye disease (TED) is an immune-mediated disorder of the eye. Intravenous glucocorticoid (GC) is the first-line treatment for patients with active moderate-to-severe TED. However, the response rate is between 50% and 80%. There are still no simple and reliable markers of responsiveness to GC therapy. We aimed to explore the possible role of miR-146a and miR-21 as predictors of responsiveness to GC treatment in TED. METHODS: We carried out a prospective longitudinal study on 30 consecutive adult patients with active moderate-to-severe TED and eligible for GC therapy. All patients received the standard GC treatment with methylprednisolone i.v. In cases of progressive worsening of Gorman Score for diplopia or with duction restriction <30° in at least two consecutive controls, patients also underwent orbital radiotherapy. Response to GC treatment was defined as a decrease of two or more points in the clinical activity score (CAS) or CAS <4/10 at 24 weeks. Circulating miRNAs were extracted from patients’ serum and quantified by real-time PCR. RESULTS: Twenty-three (77%) patients responded to GC. Thyroid surgery, higher CAS, greater proptosis and higher pre-treatment circulating levels of miR-146a emerged as predictive factors of responsiveness to GC. A ROC analysis revealed that miR-146a could predict responsiveness to GC with a positive predictive value of 100%. CONCLUSION: This is the first study investigating the role of pre-treatment circulating miR-21 and miR-146a to predict responsiveness to GC in TED. miR-146a emerged as a simple, objective, new marker of GC sensitivity that could be used to avoid ineffective administration of GC therapy to TED patients.
format Online
Article
Text
id pubmed-10563606
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-105636062023-10-11 Circulating miR-146a predicts glucocorticoid response in thyroid eye disease Manso, Jacopo Censi, Simona Clausi, Cristina Piva, Ilaria Zhu, Yi Hang Mondin, Alberto Pedron, Maria Chiara Barollo, Susi Bertazza, Loris Midena, Giulia Parrozzani, Raffaele Mian, Caterina Eur Thyroid J Research OBJECTIVE: Thyroid eye disease (TED) is an immune-mediated disorder of the eye. Intravenous glucocorticoid (GC) is the first-line treatment for patients with active moderate-to-severe TED. However, the response rate is between 50% and 80%. There are still no simple and reliable markers of responsiveness to GC therapy. We aimed to explore the possible role of miR-146a and miR-21 as predictors of responsiveness to GC treatment in TED. METHODS: We carried out a prospective longitudinal study on 30 consecutive adult patients with active moderate-to-severe TED and eligible for GC therapy. All patients received the standard GC treatment with methylprednisolone i.v. In cases of progressive worsening of Gorman Score for diplopia or with duction restriction <30° in at least two consecutive controls, patients also underwent orbital radiotherapy. Response to GC treatment was defined as a decrease of two or more points in the clinical activity score (CAS) or CAS <4/10 at 24 weeks. Circulating miRNAs were extracted from patients’ serum and quantified by real-time PCR. RESULTS: Twenty-three (77%) patients responded to GC. Thyroid surgery, higher CAS, greater proptosis and higher pre-treatment circulating levels of miR-146a emerged as predictive factors of responsiveness to GC. A ROC analysis revealed that miR-146a could predict responsiveness to GC with a positive predictive value of 100%. CONCLUSION: This is the first study investigating the role of pre-treatment circulating miR-21 and miR-146a to predict responsiveness to GC in TED. miR-146a emerged as a simple, objective, new marker of GC sensitivity that could be used to avoid ineffective administration of GC therapy to TED patients. Bioscientifica Ltd 2023-08-21 /pmc/articles/PMC10563606/ /pubmed/37606076 http://dx.doi.org/10.1530/ETJ-23-0083 Text en © the author(s) https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License. (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Research
Manso, Jacopo
Censi, Simona
Clausi, Cristina
Piva, Ilaria
Zhu, Yi Hang
Mondin, Alberto
Pedron, Maria Chiara
Barollo, Susi
Bertazza, Loris
Midena, Giulia
Parrozzani, Raffaele
Mian, Caterina
Circulating miR-146a predicts glucocorticoid response in thyroid eye disease
title Circulating miR-146a predicts glucocorticoid response in thyroid eye disease
title_full Circulating miR-146a predicts glucocorticoid response in thyroid eye disease
title_fullStr Circulating miR-146a predicts glucocorticoid response in thyroid eye disease
title_full_unstemmed Circulating miR-146a predicts glucocorticoid response in thyroid eye disease
title_short Circulating miR-146a predicts glucocorticoid response in thyroid eye disease
title_sort circulating mir-146a predicts glucocorticoid response in thyroid eye disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563606/
https://www.ncbi.nlm.nih.gov/pubmed/37606076
http://dx.doi.org/10.1530/ETJ-23-0083
work_keys_str_mv AT mansojacopo circulatingmir146apredictsglucocorticoidresponseinthyroideyedisease
AT censisimona circulatingmir146apredictsglucocorticoidresponseinthyroideyedisease
AT clausicristina circulatingmir146apredictsglucocorticoidresponseinthyroideyedisease
AT pivailaria circulatingmir146apredictsglucocorticoidresponseinthyroideyedisease
AT zhuyihang circulatingmir146apredictsglucocorticoidresponseinthyroideyedisease
AT mondinalberto circulatingmir146apredictsglucocorticoidresponseinthyroideyedisease
AT pedronmariachiara circulatingmir146apredictsglucocorticoidresponseinthyroideyedisease
AT barollosusi circulatingmir146apredictsglucocorticoidresponseinthyroideyedisease
AT bertazzaloris circulatingmir146apredictsglucocorticoidresponseinthyroideyedisease
AT midenagiulia circulatingmir146apredictsglucocorticoidresponseinthyroideyedisease
AT parrozzaniraffaele circulatingmir146apredictsglucocorticoidresponseinthyroideyedisease
AT miancaterina circulatingmir146apredictsglucocorticoidresponseinthyroideyedisease